Number of patients screened	26
Number of patients enrolled	18
Number of patients evaluable for toxicity	18
Number of patients evaluated for efficacy	18
Evaluation method	RECIST 1.1
Response assessment, CR	0(0%)
Response assessment, PR	5(27.8%)
Response assessment, SD	0(0%)
Response assessment, PD	10 (55.6%)
Response assessment, Other	3(16.7%)
(Median) duration assessments, PFS	2.1 Months; CI 2.0-4.3
(Median) duration assessments, OS	10.8 months; CI 4.3-NA
(Median) duration assessments, Response duration	2.8-NA